Cargando…
Efficacy and Safety of Rituximab for Refractory and Relapsing Thrombotic Thrombocytopenic Purpura: A Cohort of 10 Cases
OBJECTIVE: Idiopathic thrombotic thrombocytopenic purpura (TTP) is a life-threatening disorder mediated by autoantibodies directed against ADAMTS13. This provides a rationale for the use of rituximab in this disorder. We report our experience and the outcome of 10 cases of TTP (9 refractory and 1 re...
Autores principales: | Omri, Halima El, Taha, Ruba Y, Gamil, Amna, Ibrahim, Firyal, Sabah, Hisham Al, Mahmoud, Zeinab O, Pittari, Gianfranco, HIjji, Ibrahim Al, Yassin, Mohamed A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Libertas Academica
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4451552/ https://www.ncbi.nlm.nih.gov/pubmed/26052230 http://dx.doi.org/10.4137/CMBD.S25326 |
Ejemplares similares
-
Tubercular Meningitis and Lymphadenitis Mimicking a Relapse of Burkitt's Lymphoma on (18)F-FDG-PET/CT: A Case Report
por: Omri, Halima El, et al.
Publicado: (2015) -
Thrombotic thrombocytopenic purpura treated with rituximab in systemic lupus erythematosus
por: Karimifar, Mansoor
Publicado: (2012) -
Rituximab as first-line treatment for acquired thrombotic thrombocytopenic purpura
por: Chen, Haifei, et al.
Publicado: (2017) -
Thrombotic thrombocytopenic purpura
por: Knöbl, Paul
Publicado: (2018) -
Relapse Rate in Survivors of Acute Autoimmune Thrombotic Thrombocytopenic Purpura Treated with or without Rituximab
por: Falter, Tanja, et al.
Publicado: (2018)